A blood-based diagnostic test incorporating plasma Aβ42/40 ratio, ApoE proteotype, and age accurately identifies brain amyloid status: findings from a multi cohort validity analysis

[1]  W. M. van der Flier,et al.  Combination of plasma amyloid beta(1-42/1-40) and glial fibrillary acidic protein strongly associates with cerebral amyloid pathology , 2020, Alzheimer's Research & Therapy.

[2]  2020 Alzheimer's disease facts and figures , 2020, Alzheimer's & dementia : the journal of the Alzheimer's Association.

[3]  Steven W. Taylor,et al.  High-Throughput Mass Spectrometry Assay for Quantifying β-Amyloid 40 and 42 in Cerebrospinal Fluid. , 2019, Clinical chemistry.

[4]  Philip S. Insel,et al.  Cerebrospinal fluid and plasma biomarker trajectories with increasing amyloid deposition in Alzheimer's disease , 2019, EMBO molecular medicine.

[5]  James G. Bollinger,et al.  High-precision plasma β-amyloid 42/40 predicts current and future brain amyloidosis , 2019, Neurology.

[6]  L. Parnetti,et al.  The added value of Aβ42/Aβ40 in the CSF signature for routine diagnostics of Alzheimer's disease. , 2019, Clinica chimica acta; international journal of clinical chemistry.

[7]  B. Dickerson,et al.  Putting the New Alzheimer Disease Amyloid, Tau, Neurodegeneration (AT[N]) Diagnostic System to the Test. , 2019, JAMA.

[8]  S. Suppiah,et al.  The Who, When, Why, and How of PET Amyloid Imaging in Management of Alzheimer’s Disease—Review of Literature and Interesting Images , 2019, Diagnostics.

[9]  R. Batrla,et al.  Preanalytical sample handling recommendations for Alzheimer's disease plasma biomarkers , 2019, Alzheimer's & dementia.

[10]  M. Carrillo,et al.  Association of Amyloid Positron Emission Tomography With Subsequent Change in Clinical Management Among Medicare Beneficiaries With Mild Cognitive Impairment or Dementia , 2019, JAMA.

[11]  Brian A. Gordon,et al.  Assessment of Racial Disparities in Biomarkers for Alzheimer Disease , 2019, JAMA neurology.

[12]  Kathryn Goozee,et al.  A plasma protein classifier for predicting amyloid burden for preclinical Alzheimer’s disease , 2019, Science Advances.

[13]  J. Schuchhardt,et al.  A two-step immunoassay for the simultaneous assessment of Aβ38, Aβ40 and Aβ42 in human blood plasma supports the Aβ42/Aβ40 ratio as a promising biomarker candidate of Alzheimer’s disease , 2018, Alzheimer's Research & Therapy.

[14]  L. Honigberg,et al.  Preanalytical approaches to improve recovery of amyloid-β peptides from CSF as measured by immunological or mass spectrometry-based assays , 2018, Alzheimer's Research & Therapy.

[15]  Philip S. Insel,et al.  Accurate risk estimation of β-amyloid positivity to identify prodromal Alzheimer's disease: Cross-validation study of practical algorithms , 2018, Alzheimer's & Dementia.

[16]  W. M. van der Flier,et al.  Plasma Amyloid as Prescreener for the Earliest Alzheimer Pathological Changes , 2018, Annals of neurology.

[17]  C. Rowe,et al.  High performance plasma amyloid-β biomarkers for Alzheimer’s disease , 2018, Nature.

[18]  Young Ho Park,et al.  Oligomeric forms of amyloid-β protein in plasma as a potential blood-based biomarker for Alzheimer’s disease , 2017, Alzheimer's Research & Therapy.

[19]  James G. Bollinger,et al.  Amyloid β concentrations and stable isotope labeling kinetics of human plasma specific to central nervous system amyloidosis , 2017, Alzheimer's & Dementia.

[20]  Giovanni B. Frisoni,et al.  Recommendations for cerebrospinal fluid Alzheimer's disease biomarkers in the diagnostic evaluation of mild cognitive impairment , 2017, Alzheimer's & Dementia.

[21]  R. Dean,et al.  A digital enzyme-linked immunosorbent assay for ultrasensitive measurement of amyloid-β 1–42 peptide in human plasma with utility for studies of Alzheimer’s disease therapeutics , 2016, Alzheimer's Research & Therapy.

[22]  K. Blennow,et al.  CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis , 2016, The Lancet Neurology.

[23]  Erin E. Chambers,et al.  Round robin test on quantification of amyloid-β 1–42 in cerebrospinal fluid by mass spectrometry , 2016, Alzheimer's & Dementia.

[24]  Youngsoo Kim,et al.  Detection and quantification of plasma amyloid-β by selected reaction monitoring mass spectrometry. , 2014, Analytica chimica acta.

[25]  K. Blennow,et al.  Mass spectrometry-based candidate reference measurement procedure for quantification of amyloid-β in cerebrospinal fluid. , 2014, Clinical chemistry.

[26]  Nick C Fox,et al.  Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria , 2014, The Lancet Neurology.

[27]  Blaine R. Roberts,et al.  Changes in plasma amyloid beta in a longitudinal study of aging and Alzheimer's disease , 2014, Alzheimer's & Dementia.

[28]  J. Trojanowski,et al.  Plasma amyloid beta measurements - a desired but elusive Alzheimer's disease biomarker , 2013, Alzheimer's Research & Therapy.

[29]  Erin E. Chambers,et al.  Quantitation of amyloid beta peptides Aβ(1-38), Aβ(1-40), and Aβ(1-42) in human cerebrospinal fluid by ultra-performance liquid chromatography-tandem mass spectrometry. , 2011, Analytical biochemistry.

[30]  Xavier Robin,et al.  pROC: an open-source package for R and S+ to analyze and compare ROC curves , 2011, BMC Bioinformatics.

[31]  Olga Vitek,et al.  Correlation between y-type ions observed in ion trap and triple quadrupole mass spectrometers. , 2009, Journal of proteome research.

[32]  E. DeLong,et al.  Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. , 1988, Biometrics.

[33]  K. Blennow,et al.  Ultrasensitive Detection of Plasma Amyloid-β as a Biomarker for Cognitively Normal Elderly Individuals at Risk of Alzheimer's Disease. , 2019, Journal of Alzheimer's disease : JAD.

[34]  A. Van der Laarse,et al.  Automated Multiplex LC-MS/MS Assay for Quantifying Serum Apolipoproteins A-I, B, C-I, C-II, C-III, and E with Qualitative Apolipoprotein E Phenotyping. , 2016, Clinical chemistry.

[35]  A. Hammers,et al.  Diagnostic accuracy of (18)F amyloid PET tracers for the diagnosis of Alzheimer's disease , 2016 .

[36]  Jong Hun Kim,et al.  Elevation of the Plasma Aβ40/Aβ42 Ratio as a Diagnostic Marker of Sporadic Early-Onset Alzheimer's Disease. , 2015, Journal of Alzheimer's disease : JAD.